Anti-OPRK1 antibody
Specifications
| Product Cat#: | AB-07-3392 |
| Product type: | Primary antibody |
| Antigen: | OPRK1 |
| Immunogen: | A synthetic peptide derived from human OPRK1. The exact amino-acid sequence is proprietary. |
| Species immunized: | Rabbit |
| Isotype: | IgG |
| Applications: | ELISA (1:1000); Western Blot (1:500-1:2500) |
| Reactivity: | Human, Mouse, Rat |
| Clonality (clone number): | Polyclonal |
| Form: | Liquid |
| Buffer: | PBS (without Mg2+ and Ca2+ ), pH 7.4, 0.02% sodium azide and 50% glycerol |
| Concentration: | 1 mg/ml |
| Purity: | Antigen affinity chromatography |
| Storage: | Aliquot and freeze at -20°C. Avoid multiple freeze/thaw cycles. |
| Alternative names: | Kappa-type opioid receptor; MSL-1; OPRK; OPRK1; ROR-D |
Target information
G-protein coupled opioid receptor that functions as receptor for endogenous alpha-neoendorphins and dynorphins, but has low affinity for beta-endorphins. Also functions as receptor for various synthetic opioids and for the psychoactive diterpene salvinorin A. Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates the activity of down-stream effectors, such as adenylate cyclase. Signaling leads to the inhibition of adenylate cyclase activity. Inhibits neurotransmitter release by reducing calcium ion currents and increasing potassium ion conductance. Plays a role in the perception of pain. Plays a role in mediating reduced physical activity upon treatment with synthetic opioids. Plays a role in the regulation of salivation in response to synthetic opioids. May play a role in arousal and regulation of autonomic and neuroendocrine functions.
Provider
Erpantech Laboratory
